… highlight the potential of nucleic acid-based therapies (NA-BTs). Alzheimer’s Disease (AD) is
… is a cause of death and the most common form of dementia is Alzheimer's disease (AD) [1]. …

… This progress underscores the promise of leveraging nucleic acid-based approaches in
developing innovative treatments for AD. Nonetheless, utilizing nucleic acids as therapeutic …

… , Parkinson’s disease, amyotrophic lateral sclerosis, etc. Here, we will discuss the
important nucleic acid-based therapies to treat neurodegenerative diseases along with the …

… a wide range of diseases, with Alzheimer’s disease (AD), Vascular Dementia, dementia with
Lewy bodies, Frontotemporal Dementia and Parkinson’s Disease being the most relevant [2,…

… In recent years, theranostic agents have emerged as an … We review here the area of
small-molecule theranostic agents … and significant impact that theranostics can be expected to …

… There are many obstacles to the delivery of drugs into neurons of the brain for its regeneration
in Alzheimer’s disease (AD), which severely damages memory and cognitive functions of …

… and therapy) and nucleic acid-based therapies are two exciting … specificity have found many
theranostics applications, but of … gene are highly associated with Alzheimer disease, and are …

… Amyloid-β oligomer-targeted gadolinium-based NIR/MR dual-modal theranostic
nanoprobe for Alzheimer's disease. Adv Funct Mater 2020;30(16):909529; doi: 10.1002/adfm.…

There is growing need for a safe, efficient, specific and non-pathogenic means for delivery
of gene therapy materials. Nanomaterials for nucleic acid delivery offer an unprecedented …

… TLR4 has also been reported to play a role during neurodegenerative disorders,
including Alzheimer's disease, multiple sclerosis and Parkinson's disease and related α-…